Nabuton tablet should be taken orally, preferably with food or milk to minimize gastrointestinal upset. Swallow the tablet whole with a glass of water.

Nabumetone is a prodrug that is metabolized to its active form, 6-methoxy-2-naphthylacetic acid (6-MNA). 6-MNA selectively inhibits cyclooxygenase-2 (COX-2) and to a lesser extent cyclooxygenase-1 (COX-1), thereby reducing the synthesis of prostaglandins, which are mediators of inflammation and pain.

• •Hypersensitivity to Nabumetone, aspirin, or other NSAIDs.
• •History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.
• •Active peptic ulcer, gastrointestinal bleeding, or history of recurrent peptic ulceration/hemorrhage.
• •Severe heart failure, severe renal impairment, or severe hepatic impairment.
• •Third trimester of pregnancy.

Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.

Symptoms of overdose may include lethargy, drowsiness, nausea, vomiting, epigastric pain, and gastrointestinal bleeding. Rarely, hypertension, acute renal failure, respiratory depression, and coma may occur. Management is symptomatic and supportive. Gastric lavage and activated charcoal may be considered within an hour of ingestion. Monitor vital signs and renal function.

Pregnancy: Category C in first and second trimesters, but contraindicated in the third trimester due to potential adverse effects on the fetal cardiovascular system (premature closure of the ductus arteriosus) and inhibition of uterine contractions. Lactation: Nabumetone and its active metabolite are excreted in breast milk. Use is generally not recommended during breastfeeding.